Transplant characteristics
| . | Donor type . | N (%)∗ . | . | Graft manipulation . | N (%)∗ . |
|---|---|---|---|---|---|
| Missing: 7 (2.1%) | MRD | 103 (32) | Missing: 1 (0.3%) | Yes | 31 (9.5) |
| MUD (10/10) | 136 (42.2) | No | 297 (90.5) | ||
| MMUD (9/10) | 56 (17.4) | ||||
| MMUD (<9/10) | 8 (2.5) | TCR α-β depletion | 16 | ||
| UCB | 1 (0.3) | CD34+ selection | 10 | ||
| MMRD (Haplo) | 18 (5.8) | Other | 5 | ||
| Stem cell source | Conditioning regimen groups | ||||
| Missing: 1 (0.3%) | BM | 151 (46) | Missing: 2 (0.6%) | Busulfan-based | 133 (40.4) |
| PB | 169 (51.5) | Treosulfan-based | 86 (26.1) | ||
| BM+PB | 1 (0.3) | Melphalan-based | 74 (22.5) | ||
| CB† | 4 (1.2) | Other | 34 (10.4) | ||
| BM+CB | 1 (0.3) | ||||
| PB+CB | 2 (0.6) | ||||
| Conditioning regimen intensity | Most commonly used conditioning regimens | ||||
| Missing: 13 (4%) | Myeloablative | 82 (25.9) | Fludarabine, busulfan | 97 | |
| Reduced toxicity | 208 (65.8) | Fludarabine, melphalan | 56 | ||
| Nonmyeloablative | 26 (8.2) | Fludarabine, treosulfan | 42 | ||
| Fludarabine, treosulfan, thiotepa | 37 | ||||
| Busulfan, cyclophosphamide | 17 | ||||
| Fludarabine, cyclophosphamide | 13 | ||||
| Fludarabine, melphalan, thiotepa | 11 | ||||
| Fludarabine, busulfan, thiotepa | 7 | ||||
| Fludarabine, melphalan, BCNU | 7 | ||||
| Fludarabine, thiotepa | 5 | ||||
| Fludarabine | 5 | ||||
| Other | 30 | ||||
| Serotherapy | |||||
| Missing: 2 (0.6%) | Alemtuzumab | 138 (42.2) | |||
| ATG/ALG | 109 (33.3) | ||||
| No serotherapy | 80 (24.5) | ||||
| CMV match (donor/recipient) | |||||
| Missing: 69 (21%) | −/− | 74 (28.5) | |||
| −/+ | 18 (6.9) | ||||
| +/− | 60 (23.1) | ||||
| +/+ | 108 (41.5) | ||||
| Year of HSCT | |||||
| Median (IQR) | 2014 (2010-2016) | ||||
| . | Donor type . | N (%)∗ . | . | Graft manipulation . | N (%)∗ . |
|---|---|---|---|---|---|
| Missing: 7 (2.1%) | MRD | 103 (32) | Missing: 1 (0.3%) | Yes | 31 (9.5) |
| MUD (10/10) | 136 (42.2) | No | 297 (90.5) | ||
| MMUD (9/10) | 56 (17.4) | ||||
| MMUD (<9/10) | 8 (2.5) | TCR α-β depletion | 16 | ||
| UCB | 1 (0.3) | CD34+ selection | 10 | ||
| MMRD (Haplo) | 18 (5.8) | Other | 5 | ||
| Stem cell source | Conditioning regimen groups | ||||
| Missing: 1 (0.3%) | BM | 151 (46) | Missing: 2 (0.6%) | Busulfan-based | 133 (40.4) |
| PB | 169 (51.5) | Treosulfan-based | 86 (26.1) | ||
| BM+PB | 1 (0.3) | Melphalan-based | 74 (22.5) | ||
| CB† | 4 (1.2) | Other | 34 (10.4) | ||
| BM+CB | 1 (0.3) | ||||
| PB+CB | 2 (0.6) | ||||
| Conditioning regimen intensity | Most commonly used conditioning regimens | ||||
| Missing: 13 (4%) | Myeloablative | 82 (25.9) | Fludarabine, busulfan | 97 | |
| Reduced toxicity | 208 (65.8) | Fludarabine, melphalan | 56 | ||
| Nonmyeloablative | 26 (8.2) | Fludarabine, treosulfan | 42 | ||
| Fludarabine, treosulfan, thiotepa | 37 | ||||
| Busulfan, cyclophosphamide | 17 | ||||
| Fludarabine, cyclophosphamide | 13 | ||||
| Fludarabine, melphalan, thiotepa | 11 | ||||
| Fludarabine, busulfan, thiotepa | 7 | ||||
| Fludarabine, melphalan, BCNU | 7 | ||||
| Fludarabine, thiotepa | 5 | ||||
| Fludarabine | 5 | ||||
| Other | 30 | ||||
| Serotherapy | |||||
| Missing: 2 (0.6%) | Alemtuzumab | 138 (42.2) | |||
| ATG/ALG | 109 (33.3) | ||||
| No serotherapy | 80 (24.5) | ||||
| CMV match (donor/recipient) | |||||
| Missing: 69 (21%) | −/− | 74 (28.5) | |||
| −/+ | 18 (6.9) | ||||
| +/− | 60 (23.1) | ||||
| +/+ | 108 (41.5) | ||||
| Year of HSCT | |||||
| Median (IQR) | 2014 (2010-2016) | ||||
ATG/ALG, antithymocyte globulin/antilymphocyte globulin; BCNU, carmustine; BM, bone marrow; CB, cord blood; Haplo, haploidentical; MAbs, monoclonal antibodies; MMRD, mismatched-related donor; MMUD, mismatched unrelated donor; MRD, matched-related donor; MUD, matched unrelated donor; PB, peripheral blood; TCR, T-cell receptor; UCB, unrelated umbilical cord blood.
Percentages in this column are calculated from the nonmissing.
One unrelated cord blood, all others from related donors.